Latest news with #RajaBhanu
Hans India
25-05-2025
- Business
- Hans India
Centre invites drugmakers to apply for PLI scheme aimed at boosting key medicines production
New Delhi: The Department of Pharmaceuticals has invited applications from drug manufacturers under the Production Linked Incentive (PLI) scheme to set up new manufacturing units for 11 key pharmaceutical products. This move aims to strengthen India's domestic drug production capabilities. The products include important antibiotics and painkillers such as Neomycin, Gentamycin, Erythromycin, Streptomycin, Tetracycline, Ciprofloxacin, and Diclofenac Sodium. These medicines are either unsubscribed or only partially subscribed under the earlier phases of the scheme. Manufacturers can submit their applications until June 14. The PLI scheme comes with certain conditions. Incentives will be provided based on available capacity, a defined ceiling for each product, and the production timeline. For chemical synthesis products, the incentive period will last until the financial year 2027-28, while for fermentation-based products, it will extend up to 2028-29. However, companies that were previously approved and later withdrew or had their approvals cancelled are not eligible to reapply. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has encouraged its members to make the most of this opportunity. Pharmexcil Director General Raja Bhanu said the scheme offers a significant chance for companies to boost their manufacturing capacity in essential drug ingredients. This fresh call for applications is part of the government's ongoing push to promote domestic production of critical Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs). The PLI scheme for these categories was first introduced in 2020 and later revised to better suit the industry's needs. It covers a total of 41 products and has a financial outlay of Rs 6,940 crore. The initiative is part of a broader effort by the government, which launched PLI schemes for 14 major sectors four years ago. These include bulk drugs, medical devices, electronics, food processing and automobiles. According to official data, till November 2024, about 764 applications had been approved under these schemes, leading to an investment of Rs 1.61 lakh crore (around $18.7 billion). The government has disbursed Rs 14,020 crore in incentives so far under 10 sectors.
The Hindu
24-05-2025
- Business
- The Hindu
PLI scheme for 11 pharma products rolled out
The Centre's Department of Pharmaceuticals is inviting applications from drugmakers for a production linked incentive (PLI) scheme to encourage setting up new manufacturing capacities for as many as 11 eligible products. Neomycin, Gentamycin, Erythromycin, Streptomycin, Tetracycline, Ciprofloxacin and Diclofenac Sodium figure in the list. These are either unsubscribed or partially subscribed eligible products, the Department said in a notification earlier this month. June 14 has been set as the last date for the manufacturers to submit the applications. Conditions such as allocation according to available capacities, incentive ceiling in respect of products, and limit of incentive up to the production tenure, which will be up to FY28 for chemical synthesis products and up to FY29 for fermentation-based products, have to be complied with. Companies that were granted approval earlier, but subsequently withdrew or whose approval was cancelled are not eligible to apply, it said. The Pharmaceuticals Export Promotion Council of India has urged its members to take advantage of the decision. The scheme presents a significant opportunity to enhance their manufacturing capabilities in critical pharmaceutical components, Pharmexcil Director General Raja Bhanu said. The Department of Pharmaceuticals' decision is in continuation of India's emphasis on encouraging domestic manufacturing of critical key starting materials, drug intermediates and active pharmaceutical ingredients. Four years ago the government had rolled out PLI schemes for 14 key sectors, which included bulk drugs, medical devices and pharma, with an eye on boosting production, generating jobs and boosting exports by incentivising domestic manufacturing. The scheme for KSMs, DIs and APIs, whose guidelines were issued in July 2020 and revised in October the same year, cover a total of 41 products and has a financial outlay of ₹6,940 crore, as per official documents. In March 2025, the government had announced that 764 applications have been approved under the schemes for the 14 key sectors and investment of around ₹1.61 lakh crore ($18.72 billion) reported till November 2024. Incentive of around ₹14,020 crore have been disbursed under the PLI schemes for 10 sectors, including large-scale electronics manufacturing (LSEM), IT hardware, bulk drugs, medical devices, pharmaceuticals, telecom and networking products, food processing, white goods, automobiles and auto components and drones and drone components.
News18
28-04-2025
- Business
- News18
India Seeks List Of Medicines, Pharma Products Exported To Pakistan On 'Urgent' Basis
Last Updated: In wake of the Pahalgam terror attack, the department of pharmaceuticals has sought pharmaceutical export data from Pharmexcil, an arm under the ministry of commerce and industry Amid the growing strain on bilateral trade relations, the department of pharmaceuticals has requested the pharma export body to prepare a list of medicines and pharmaceutical products exported to Pakistan. The move was triggered by the terror attack in Pahalgam, which claimed 26 lives. Accusing Pakistan of backing cross-border terrorism, India announced a raft of measures against its neighbour. Islamabad, however, has denied the allegations and retaliated with reciprocal steps against Delhi, including snapping trade ties. The department of pharmaceuticals (DoP) under the ministry of chemicals and fertilisers has sought details from Pharmexcil – an arm that functions under the ministry of commerce and industry. 'We have asked for the export data to see what we are sending to Pakistan. Pharmaceuticals Export Promotion Council of India (Pharmexcil) is working on it and will send details soon," a senior government official told News18. The DoP has requested the information on an 'urgent" basis. According to Pharmexcil data, Pakistan is the 38th out of 219 countries in India's pharmaceutical exports market. In the fiscal 2023, India exported $191.36 million followed by $176.54 million in the fiscal 2024. The latest data pegs trade at around $200 million. 'Dubai is a major business trading centre for Pakistan. While India exports medicines and pharma products to the UAE, in turn, Pakistan imports from these countries," another government official told News18, while explaining the pharmaceutical trade relationship between India and Pakistan. 'The majority of Indian exports to Pakistan include active pharmaceutical ingredients (APIs). While it won't impact India by snapping the pharma trade ties, it will impact Pakistan as it would import costlier drugs and APIs from the countries rerouting our medicines," the official said. Also known as bulk drugs, APIs are the therapeutic agents that give the main effect to the medicine. For instance, paracetamol is an API in the Crocin tablet. News18 contacted Raja Bhanu, director general of Pharmexcil and secretary of the DoP, for comments. Repeated calls and text messages to him went unanswered. It is not the first time the two countries have faced a strained bilateral relationship. Following the Balakot airstrikes and the abrogation of Article 370, former Pakistan Prime Minister Imran Khan had banned bilateral trade with India. Pakistan, however, later relaxed the restrictions for several categories, including pharmaceuticals, reflecting the importance of the sector. First Published:
